explore -WSS

explore

author：fashion 2025-09-06 03:28:17 - browse：84443

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Food makers to regulators: Ultra

hotspot

WSS

Walmart eyes Medicare Advantage provider ChenMed

White House touts steps to stem shortages of cancer treatments

Pharma companies must ensure equitable access to obesity drugs

STAT Virtual Event: ASCO Recap, Live!

New report analyzes digital physical therapy solutions' effectiveness

New weight loss drugs vying to be the next Wegovy or Mounjaro

knowledge

explore

focus

The high cost of giving birth even with insurance

Readers discuss the intersection of pregnancy and addiction

Walensky prepares to leave CDC — and Congress — behind

Moderna says combo Covid

Virginia high school admissions case could be legal follow

Private equity could exacerbate cardiology's overuse problem, experts fear

Trump demands the U.S. pay no more for drugs than other countries … again

The system is set up to fail children with medical complexity

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Teladoc has a new CEO, but challenges remain the same

Wikipedia

Stephen Quake on the Chan Zuckerberg quest to conquer disease

5 takeaways from STAT's examination of Zynex Medical

Food makers tried to stack nutrition panel with preferred experts

Long Covid needs a new name — and a new frame

Medical device trials still don't enroll enough women, study finds

NIH tests clinical research in primary care with $30 million program

focus

hotspot

hotspot

hotspot